LAUSR

We described a reduction of target of Myb1 (TOM1) protein levels by Western blot in the postmortem hippocampus of subjects with Alzheimer’s disease (AD) versus nondemented subjects (1), validating similar findings by an independent research group in a separate human cohort (2). Based on single-cell transcriptomic data (3), Peng and Zhao (4) conclude that TOM1 levels are, contrariwise to our findings, higher in AD. Although we do not disagree with their hypothesis that TOM1 expression could be up-regulated in AD, at least at early disease stages, precautions should be taken when comparing our findings to theirs. First, we determined the protein levels in the hippocampus whereas the RNAseq was performed in the prefrontal cortex. Discrepancies could therefore be related to … [↵][1]1To whom correspondence may be addressed. Email: d.baglietto{at}uci.edu, rodrigo.medeiros{at}neurula.org, or laferla{at}uci.edu. [1]: #xref-corresp-1-1